Psilocybin vs Antidepressants: What the Head-to-Head Trial Found
In 2021, Imperial College London published the first head-to-head trial comparing psilocybin to an SSRI antidepressant. Here's what they found — and what it means for treatment-resistant depression.
In April 2021, Imperial College London published the first randomized controlled trial directly comparing psilocybin to an SSRI antidepressant. The results were published in The New England Journal of Medicine — one of the most prestigious medical journals in the world.
Here's what they found.
The Trial Design
Published in: The New England Journal of Medicine
Lead researcher: Robin Carhart-Harris
Enrolled: 59 adults with moderate-to-severe major depressive disorder
Design: Double-blind, randomized controlled trial
Participants were randomly assigned to:
Both groups received the same amount of psychological support.
The Primary Outcome
The primary outcome was change in depression severity (QIDS-SR-16 score) at 6 weeks.
Result: Both groups showed significant reductions in depression severity. The psilocybin group showed slightly larger reductions, but the difference was not statistically significant.
At first glance, this looks like a tie. But the secondary outcomes tell a more interesting story.
The Secondary Outcomes
The secondary outcomes showed consistent advantages for psilocybin:
Remission rates: 57% of psilocybin participants achieved remission (QIDS-SR-16 score ≤5) vs 28% of SSRI participants.
Response rates: 70% of psilocybin participants showed a significant response vs 48% of SSRI participants.
Emotional processing: Psilocybin participants showed significantly greater improvements in "emotional blunting" — the emotional flatness that is a common complaint with SSRIs. The psilocybin group reported feeling more emotionally connected and alive.
Psychological flexibility: Psilocybin participants showed significantly greater improvements in psychological flexibility — the ability to adapt thoughts and behaviors to changing circumstances.
Wellbeing and meaning: Psilocybin participants reported significantly greater improvements in overall wellbeing, sense of meaning, and connectedness.
What This Means
The trial was not powered to detect a statistically significant difference between groups on the primary outcome — it was designed as a feasibility study. But the pattern of secondary outcomes is striking: psilocybin produced similar or superior antidepressant effects with additional benefits in emotional processing, psychological flexibility, and wellbeing that SSRIs don't produce.
The SSRI group showed the typical SSRI pattern: reduced depression symptoms but also reduced emotional range. The psilocybin group showed reduced depression symptoms with enhanced emotional range.
This article is for informational purposes only and does not constitute medical advice.
This article is for informational purposes only and does not constitute medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before making any changes to your health regimen.